PSUSA/00010473/202503

PSUSA/00010473/202503

Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Date of authorisation: 12/01/2005, Revision: 67, Status: Authorised

Human medicines European public assessment report (EPAR): Fabhalta, iptacopan, Date of authorisation: 17/05/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Date of authorisation: 17/07/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Minjuvi, tafasitamab, Date of authorisation: 26/08/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Replagal, agalsidase alfa, Date of authorisation: 03/08/2001, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Viatris (previously Pregabalin Mylan), pregabalin, Date of authorisation: 24/06/2015, Revision: 23, Status: Authorised